283 results about "Carbonic anhydrase" patented technology

Disclosed herein is the discovery of a soluble MN / CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The Predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50 / 54 kilodaltons (kd) upon Western blot. A smaller s-CA IX form of about 20 to about 30 kd comprising the CA domain or parts thereof, not linked to the PG domain, has also been found in body fluids. Diagnostic / prognostic methods for precancer and cancer that detect or detect and quantitate said s-CA IX in body fluids, are described. Also disclosed herein is the coexpression of CA IX and HER-2 / neu / c-erbB-2 that provides parallel, alternative and potentially synergistic diagnostic / prognostic and therapeutic strategies for precancer and cancer. Further disclosed are new MN / CA IX-specific antibodies generated from MN / CA IX-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Such new MN / CA IX-specific antibodies, fragments and variants are useful diagnostically / prognostically and therapeutically for cancer and precancer. Particularly preferred are the new monoclonal antibodies, fragments and variants that are specific for the non-immunodominant epitopes of MN / CA IX, which antibodies are, among other uses, useful to detect soluble MN / CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN / CA IX, for example, in a sandwich assay.

Disclosed herein is the discovery of a soluble MN / CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50 / 54 kilodaltons. Diagnostic / prognostic methods for precancer / cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic / prognostic and therapeutic strategies for precancer / cancer. Further disclosed are new MN / CA IX-specific antibodies generated from MN / CA IX-deficient mice, useful diagnostically / prognostically and therapeutically for cancer / precancer. Preferred are new antibodies, specific for non-immunodominant epitopes of MN / CA IX, useful to detect soluble CA IX (s-CA IX) in body fluids, preferably in combination with antibodies specific to immunodominant epitopes of MN / CA IX.

Disclosed is a formulation for the absorption of CO2, which comprises water, at least one CO2 absorption compound and a carbonic anhydrase as an activator to enhance the absorption capacity of the CO2 absorption compound. The invention also concerns the use of carbonic anhydrase, in a CO2 absorption solution to increase the CO2 absorption rate of such solution.

There is provided a microchip-based differential-type carbon dioxide gas sensor for detecting dissolved carbon dioxide levels. It functions with at least one working electrode composed of an unbuffered hydrogel membrane containing a certain amount of sodium bicarbonate and a pH-sensitive gas-permeable membrane; and a reference electrode composed of a buffered hydrogel membrane and a pH-sensitive gas-permeable membrane. The unbuffered hydrogel membrane contains carbonic anhydrase, which reduces the time period for the hydration of carbon dioxide, thereby allowing the quick measurement of the level of carbon dioxide. In addition to being significantly improved in stabilization, sensing, and recovering time periods, the differential-type carbon dioxide gas sensor can be fabricated in small sizes and quickly measure levels of carbon dioxide dissolved in sample solution.

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein.

Disclosed is a formulation for the absorption of CO2, which comprises water, at least one CO2 absorption compound and a carbonic anhydrase as an activator to enhance the absorption capacity of the CO2 absorption compound. The invention also concerns the use of carbonic anhydrase, in a CO2 absorption solution to increase the CO2 absorption rate of such solution.

Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA- IX, and a radionuclide adapted for radioimaging and / or radiotherapy.

The invention relates to a process of fermenting plant material in a fermentation medium into a fermentation product using a fermenting organism, wherein one or more carbonic anhydrases are present in the fermentation medium.

The present invention provides bioactive hollow nano-fibers and hollow microcapsules for efficiently catalyzing methanol synthesis through CO2. According to the present invention, a coaxial co-spinning technology is used to embed three enzymes for catalyzing methanol synthesis through CO2 and comprising formic dehydrogenase, formaldehyde dehydrogenase and ethanol dehydrogenase, and coenzyme NADH into the chamber of polyelectrolyte-doped hollow nano-fibers or hollow microcapsules; in order to achieve coenzyme regeneration, an oxidation reduction enzyme R adopting NAD<+> as coenzyme is embedded into the chamber; in order to accelerate a CO2 hydration reaction, carbonic anhydrase is immobilized on the outer surface of the hollow nano-fibers or hollow microcapsules through a layer-by-layer self-assembly technology; the small molecule NADH is bound on the inner wall of the hollow nano-fibers or hollow microcapsules through the electrostatic interaction between the NADH and the polyelectrolyte in the shell layer so as to achieve the recycling; and the polyelectrolyte-doped hollow nano-fiber or hollow microcapsule CO2 conversion catalyst has advantages of simple preparation, high conversion rate, and high stability, and provides wide application prospects in the field of the conversion of CO2 into methanol.

Disclosed is a formulation for the absorption of CO2, which comprises water, at least one CO2 absorption compound and a carbonic anhydrase as an activator to enhance the absorption capacity of the CO2 absorption compound. The invention also concerns the use of carbonic anhydrase, in a CO2 absorption solution to increase the CO2 absorption rate of such solution.

The invention discloses a protein and amorphous metal organic framework compound and a preparation method thereof. The organic framework compound has a 2 nm-50 nm mesoporous structure. The preparationmethod comprises the following step of enabling a protein, zinc ions and an organic ligand to react in a solvent, wherein the organic ligand is a compound containing an imidazole group; the protein is one or a combination of several kinds of cytochrome C, cytochrome P450, horse radish peroxidase, alcohol dehydrogenase, lipase, acetylcholin esterase, laccase, a green fluorescent protein, glucose dehydrogenase, glucose oxidase, trypsin, bacillus subtilis protease, carbonic anhydrase, aldehyde ketone reductase, amylase, saccharase, superoxide dismutase, urease and catalase. The preparation method of the protein and amorphous metal organic framework compound provided by the invention is simple to operate and mild in condition, the obtained product is high in protein embedding rate and good inprotein stability, and the biologic al activity of the protein is reserved to a greater extent.